← Trials/Trial dossier/NCT05268627
Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss
Lead sponsor
Assets
GLP-1 / incretin class catch-all / Liraglutide
Listed sites
2
Recruiting sites
2
Enrollment
38
estimated
Study population
Obesity / overweight
Key I/E criterion
•BMI ≥30
Primary endpoints
•Body weight, absolute change (kg)•BMI, change•Waist circumference, change
Footprint
Where this trial recruits
Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.
Identifiers
Registered as
Timeline
Milestones
Assets
Investigational agents
Study populations
Who this study enrolls
Eligibility
Who can enroll
Inclusion criteria
Sex: both Age: from 20 to 60 years Body Mass Index > 30
Exclusion criteria
Age: below 20 or above 60 years old. Patient with known gastroparesis Peptic ulcer disease or active upper gastrointestinal ulceration Prior gastric or small bowel surgery American Society of Anesthesiologists (ASA) class 3 or higher Patients with more than mild , infrequent symptoms of upper abdominal pain or nausea Pregnant or lactating female Contraindications of sedation (Uncontrolled Diabetes Mellitus, Uncontrolled Thyroid Disorders, Pregnancy, Respiratory Embarrassment, Reactional Drugs like Antidepressants and Anti-anxiety Agents).
Endpoints (4)
What's being measured
Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.
Weight & body composition
4 endpointsweight loss
Time frame:1 year
Body weight, absolute change (kg)
change from baseline, improvement
Body mass index
Time frame:1 year
BMI, change
change from baseline, improvement
waist circumference
Time frame:1 year
Waist circumference, change
change from baseline, improvement
hip circumference
Time frame:1 year
change from baseline, improvement
Provenance
Sources
Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.